Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from the C-terminal sequence of human VEGI.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Members in the TNF and its receptor superfamilies regulate immune responses and induce apoptosis. DR3 (also termed Wsl-1, Apo-3, TRAMP, and LARD) is preferentially expressed by T lymphocytes and upregulated during T cell activation. The ligand for DR3 was recently identified and designated TL1A. TL1A also binds decoy receptor DcR3/TR6, which is expressed in several lung and colon carcinomas and in some normal tissues. TL1A induces apoptosis and NF-kappa-B activation in DR3 expressing cells, which is antagonized by DcR3. TL1A is upregulated by proinflammatory cytokines TNF and IL-1. TL1A is a longer variant of TL1 (also called VEGI).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
TL1; TL1A; TNF ligand-related molecule 1; TNF superfamily ligand TL1A; tumor necrosis factor (ligand) superfamily member 15; tumor necrosis factor (ligand) superfamily, member 15; tumor necrosis factor ligand 1B; Tumor necrosis factor ligand superfamily member 15; Vascular endothelial cell growth inhibitor; vascular endothelial growth inhibitor-192A; VEGI; VEGI192A
TL1; TL1A; TNFSF15; TNLG1B; VEGI; VEGI192A